Background. Despite viral suppression, antiretroviral therapy (ART) does not restore CD4 + T-cell counts in many patients infected with human immunodeficiency virus type 1 (HIV-1).
The majority of patients with suppression of human immunodeficiency virus type 1 (HIV-1) who are receiving antiretroviral therapy (ART) have substantial recovery of CD4 + T-cell counts, with a mean increase of 176 cells/µL (95% confidence interval [CI] , 170-183) over the first year of treatment [1] . However, a French cohort study found that 17% of patients initiating a protease inhibitor-based regimen had an increase of <50 cells/µL after 6 months despite having virologic suppression [2] . The risk of disease progression was twice as high in this subset as compared to the group with both an immunologic and virologic response. The ART Cohort Collaboration found that subjects with a CD4 + T-cell count of <200 cells/µL 6 months after initiating ART were at significantly increased risk of AIDS or death as compared to those with a CD4 + T-cell count of >200 cells/µL, even after control for plasma HIV-1 RNA level [3] . Moreover, recent studies have established that CD4 + T-cell count is related to overall mortality and incidence of non-AIDS-defining cancer, even among subjects with a CD4 + T-cell count of >350 cells/µL [4, 5] .
A meta-regression of phase 2 and 3 clinical trials of investigational ART agents found that the increase in CD4 + T-cell count in groups using a CCR5 antagonist was 30 cells/µL higher than that in groups not using a CCR5 antagonist, after control for differing rates of virologic suppression [6] . Similarly, greater recovery in CD4 + T-cell count was observed in a phase 3 trial comparing combination regimens with maraviroc, a CCR5 antagonist, or with efavirenz, a nonnucleoside reversetranscriptase inhibitor (NNRTI), for initial ART of HIV-1-infected patients [7] . While maraviroc did not meet prespecified criteria in that study for a noninferiority comparison with efavirenz for virologic suppression, subjects receiving maraviroc had a significantly greater increase in CD4 + T-cell count 48
weeks after randomization as compared to those receiving efavirenz (change from baseline, +170 vs +144 cells/µL; difference, 26 cells/µL [95% CI, 7-46]) [7] . Given the potential benefit of maraviroc on CD4 + T-cell recovery, we designed and conducted AIDS Clinical Trials Group (ACTG) protocol A5256, a single-arm, multicenter, open-label clinical trial designed to test the hypothesis that adding the CCR5 inhibitor maraviroc will result in a CD4 + T-cell count increase of at least 20 cells/µL over 24 weeks in ART recipients with a rigorously defined suboptimal CD4 + T-cell recovery despite sustained virologic suppression.
METHODS
Institutional review board approval was obtained at each participating clinical site. All subjects provided written informed consent, and the human-experimentation guidelines of the US Department of Health and Human Services were followed in the conduct of this research.
Study Participants
Participants were enrolled at 29 clinical trials units. Eligible participants were HIV-1-infected males and females aged ≥16 years who had been receiving a stable ART regimen for at least 48 weeks, had had a plasma HIV-1 RNA load below the limit of detection of the assay for at least 48 weeks, and had had stable but suboptimal CD4 + T-cell recovery over the previous year (defined as a CD4 + T-cell count of <250 cells/µL and a calculated slope of the annual change in CD4 + T-cell count ranging from −20 to +20 cells/µL during the year before enrollment). Study exclusions were an uncontrolled medical condition or recent AIDS-defining illness, current receipt of immunomodulatory agents, current pregnancy or breastfeeding, or prior exposure to a CCR5 antagonist.
Study Design
ACTG A5256 was a 48-week, single-arm, open-label clinical trial in which HIV-1-infected participants with suboptimal CD4 + T cell recovery added maraviroc (Pfizer) to their existing ART regimen for 24 weeks and then discontinued maraviroc and were followed for an additional 24 weeks. The study was designed to enroll 32 patients. The maraviroc dose was 150-600 mg twice daily, depending on pharmacokinetic interactions with prestudy medications, as specified in the package insert. Participants with virologic failure (defined as 2 consecutive measurements of HIV-1 RNA levels at or above the limit of detection of the assay used at local sites) discontinued maraviroc. Participants had 2 baseline assessments prior to starting maraviroc. Participants were seen at 4, 8, 12, 16, 22 , and 24 weeks after starting maraviroc, and then at weeks 36, 46, and 48 (12, 22 , and 24 weeks after maraviroc discontinuation). Coreceptor Tropism on Proviral DNA DNA was extracted from cryopreserved cell pellets obtained from participants prior to receiving maraviroc and used as template for nested and overlapping polymerase chain reaction amplification of full-length env, using a previously described method [8] . Briefly, pseudoviral stock was generated from each of the env amplicons, with an attached CMV promoter, by cotransfection into 293T cells with an HIV plasmid (pNL4-3.Luc. R-E-) containing a nonfunctional env. The coreceptor used by the viral quasi-species was determined by infection of U87.CD4. CCR5 and U87.CD4.CXCR4 cells, with viral entry indicated by expression of the luciferase gene and ablation of the signal in the presence of the specific coreceptor inhibitor.
Immunologic Analyses

Biomarker Analysis
Plasma samples were analyzed for biomarkers, using a multiplexing sandwich enzyme-linked immunosorbent assay system based on chemiluminescent or fluorescent detection of analytes whose respective capture-antibodies are spotted in arrays within each well of a 96-well microplate (Aushon Biosystems, Billerica, MA). The analytes included a marker of gut microbial translocation (soluble CD14 [sCD14]) and inflammatory markers associated with atherosclerosis (D-dimer, highsensitivity C-reactive protein, interleukin 6, soluble intercellular cell adhesion molecule 1, monocyte chemoattractant protein 1, monocyte chemoattractant protein 2, plasma P-selectin, soluble tumor necrosis factor receptor type II, matrix metalloproteinase 9, and plasma CD40 ligand).
Statistical Analyses
The primary end point was the change in CD4 + T-cell count from the average of the 2 baseline assessments (before entry and entry) to the average of the week 22 and 24 assessments. The study was designed to have 80% power to show that the addition of maraviroc was associated with a CD4 + T-cell count increase of at least 20 cells/µL over 24 weeks, using a 1-sided Wilcoxon signed-rank test. This assumed an underlying change in CD4 + T-cell count induced by maraviroc of 50 cells/µL, a SD of 60 cells/µL around the mean change in CD4 + T-cell count, a loss to follow-up or premature maraviroc discontinuation rate of 10%, and a 1-sided type 1 error of 0.05. The estimated median change in CD4 + T-cell count and accompanying exact Hahn and Meeker 90% confidence intervals (CIs) are presented. The before-and-after treatment slopes and the difference between them are summarized across the population by using generalized estimating equations. Secondary objectives were to investigate the persistence of the increase in CD4 + T-cell count after maraviroc receipt, the mechanisms by which maraviroc influences the CD4 + T-cell responses (immunologic markers for activation, proliferation, senescence, and apoptosis), the effect of maraviroc on gut microbial translocation and inflammatory markers associated with atherosclerosis, and the relationship of viral coreceptor tropism to study outcomes. Given the exploratory nature of our secondary objectives, formal hypothesis testing was not planned; rather, median distributional shifts were estimated with 90% exact Hahn and Meeker CIs. , and having a plasma HIV-1 RNA load above the assay limit. Of 34 participants enrolled, 2 (6%) experienced virologic failure at study entry despite having virologic suppression prior to entry and were excluded from the analysis per protocol. One completed follow-up, and one left the study at 12 weeks. One additional subject was unable to attend clinic visits after 22 weeks of follow-up.
RESULTS
Baseline Characteristics and Subject Disposition
CD4
+ /CD8 + T-Cell Count Changes Figure 1B shows the change in CD8 + T-cell count from baseline over time.
Markers of Immune Activation, T-Cell Subsets, Proliferation, Apoptosis, and Senescence
The median changes (90% CIs) in the frequency of proliferation, activation, apoptotic, and senescent T-cell subsets are shown in Figures 2 and 3 (Figures 2A and 3A) . These changes were partially reversed after discontinuation of maraviroc ( Figures 2B and 3B ).
For instance, in the HLA-DR + /CD38 + subset, the median change during maraviroc administration was −1.3% (90% CI, −1.8% to −0.3%) in CD4 + T cells and − Figure 2A ), which partially reversed after maraviroc discontinuation (−0.4%; 90% CI, −0.6% to +0.6%); Figure 2B ). We also observed an increase in the percentage of BCL-2 − and a decrease in the percentage of caspase3 + CD4 + and CD8 + T cells, consistent with reduced levels of apoptosis in T cells. For changes in the percentage of BCL-2 − CD4 + and CD8 + T cells during maraviroc administration, the 90% CI contained 0, which is consistent with no change (Figures 2 and 3) . None of the changes in the various T-cell subsets was associated with the changes in CD4 + T cells with maraviroc use (data not shown).
Coreceptor Tropism
We attempted HIV-1 proviral DNA coreceptor tropism testing on samples from 29 of 32 participants in the primary analysis (3 had no samples available). Of the 18 participants with available results (samples for 11 were not able to be amplified), 11 (61%) had CCR5-tropic virus, 5 (28%) had dualtropic/mixed infections, and 2 (11%) had CXCR4-tropic virus. The study end points did not vary appreciably when comparing individuals with CCR5-tropic virus to those with dualtropic/mixed infections or CXCR4-tropic virus (P > .3, by the exact Wilcoxon rank-sum test).
Biomarker Analysis
The changes in plasma biomarkers are shown in Table 1 .
There was a median change from baseline to week 22/24 in Ddimer of +0.09 µg/mL (90% CI, +.06 to +.13), with a median baseline value of +0.33 µg/mL. In a post hoc analysis, we performed D-dimer testing on stored specimens, using a different assay (Asserachrom D-Dimer, Diagnostica Stago; Asnières, France). These results showed a median change from baseline to week 22/24 in D-dimer of +0.007 µg/mL (90% CI, −.001 to +.024), with a median baseline value of +0.13 µg/mL. There were no other appreciable changes in plasma biomarkers or sCD14 resulting from maraviroc administration.
Virologic Outcomes
Two participants experienced confirmed virologic failure while receiving maraviroc; both had a detectable HIV-1 RNA load at their entry visit, just prior to initiation of maraviroc. Two participants experienced confirmed virologic failure with their initial rise at visit week 24, when maraviroc was discontinued. The initial rise and confirmation values were 101 and 62 copies/mL and 88 780 and 340 copies/mL, respectively, for these 2 participants. Furthermore, 2 participants had unconfirmed elevations in plasma HIV-1 RNA at the final study visit with values of 99 copies/mL and 174 copies/mL respectively.
Safety Analyses
After exclusion of a case of hyperbilirubinemia due to atazanavir, there were 4 participants who reported a grade 3 sign, symptom, or laboratory abnormality (ie, hypoalbuminemia, hypocalecmia, hyperglycemia, and bradycardia) that occurred during maraviroc administration and 1 participant who reported a grade 3 event (ie, dyspnea) that occurred after maraviroc discontinuation. There were no grade 4 events reported among study participants, and no one discontinued maraviroc because of adverse events.
DISCUSSION
In a population with suboptimal CD4 + T-cell counts after a median of 3 years of virologic suppression, adding maraviroc did not lead to an appreciable increase in CD4 + T-cell counts.
Our data showed a detectable increase in CD4 + T-cell counts, but we felt the observed effect was not large enough to merit further study of this agent to improve CD4 + T-cell counts in patients with suboptimal recovery. There are no accepted therapies for increasing CD4 + T-cell counts other than suppressive ART. Interleukin 2 increased CD4 + T-cell counts but did not reduce AIDS-defining events or overall mortality [9] . Suboptimal CD4 + T-cell responses have been associated with a variety of factors, including older age and lower thymic function [10] , nadir CD4 + T-cell counts of <200 cells/µL [11] , some ART drugs (eg, zidovudine [12] and the combination of didanosine and tenofovir [13] ), CD4 + T-cell hyperactivation [14] , and increased cell death by apoptosis [15, 16] . In randomized treatment trials, a suboptimal increase in CD4 + T-cell count in the setting of virologic suppression has been associated with older age, female sex, a higher CD4 + naive T-cell level, a higher CD4 + naive/memory T-cell ratio, a lower CD8 + memory T-cell level, and a higher proportion of activated CD4 + and CD8 + T cells [17] [18] [19] .
Although the hypothesized increase in CD4 + T cells was not found, we did observe decreases in the frequency of activated CD4 + and CD8 + T cells, as well as improved markers of T-cell apoptosis in both CD4 + and CD8 + T cells. Moreover, these changes generally reversed after discontinuing maraviroc, which supports but not establish a causal effect. The β-chemokines CCL3, CCL4, and CCL5 bind to CCR5 on T cells and trigger their activation through a pathway mediated by nuclear factor of activated T cells [20] . Maraviroc inhibits the binding of β-chemokines to CCR5, and this may explain the decreases in levels of immune activation seen in this study.
Adding maraviroc was also associated with decreased peripheral blood naive and central memory CD4 + /CD8 + T cells and increased effector memory and T EMRA CD4 + /CD8 + T cells.
This may reflect redistribution of these T-cell subsets between the peripheral blood and tissue compartments. CCR5-β-chemokine interaction also modulates the chemotaxis of CCR5 + cells along a chemokine concentration gradient, allowing for directed migration of immune cells between different tissue compartments [21] [22] [23] . Maraviroc may also influence this process [24] . On the basis of HIV-1 proviral DNA tropism testing, we did not detect differences between these changes in participants harboring CCR5-tropic virus as compared to those with CXCR4-tropic, dual-tropic, or mixed infections, suggesting viral tropism may not affect the immunologic effects of maraviroc. In contrast to A5256, a small, randomized, placebo-controlled trial of maraviroc in a similar population found that the percentage of CD38 + /HLA-DR + CD8 + T cells increased slightly in the maraviroc group, compared with a decrease in the placebo group [25] . The differing results between studies were driven by the large decrease in CD38-expressing T cells in A5256. Immunophenotyping was performed on fresh cells in A5256, whereas in the study by Hunt et al, cryopreserved cells were used. We repeated immunophenotyping by using cryopreserved cells from 17 A5256 participants with available samples. We found that CD38 expression was lower in cryopreserved cells as compared to fresh cells at baseline, with no appreciable difference at week 24. Consequently, the observed changes from baseline to week 24 in cryopreserved cells were not consistent with a decrease in immune activation. A number of confounding factors, such as different sample processing, shipping season, and underlying levels of activation, could have contributed to the discrepant results observed with cryopreserved cells. Ultimately, to fully explain these differences and understand the optimal processing conditions for immunophenotyping, further independent study under controlled conditions is required. An additional randomized clinical trial [26] and single-arm trial [27] involving patients with poor CD4 + T-cell recovery found declines in immune activation markers after the addition of maraviroc to a suppressive regimen, although these changes were not different than those for placebo for the randomized clinical trial. An increase in CD8 + T-cell counts was observed in this study. A similar effect has been seen in other maraviroc clinical trials [28] . The clinical significance of this finding is unknown. Plasma D-dimer levels showed an unexpected increase after the addition of maraviroc; however, when D-dimer levels were retested post hoc using a different assay, we did not find an appreciable increase in D-dimer levels. The persistently elevated levels of activation and inflammation in HIV-1-infected persons treated with ART may explain the greater prevalence of cardiovascular, hepatic, and renal diseases, neurocognitive dysfunction, and non-AIDS-related malignancies in this population [29] [30] [31] [32] [33] [34] . Currently, there are no accepted therapies other than suppressive ART to reduce immune activation. The mechanism by which maraviroc may reduce immune activation is unclear. CCR5 binding by β-chemokines promotes T-cell activation and proliferation. CCR5 antagonists may downmodulate T-cell activation by preventing this interaction.
There are several limitations to this study. This was a singlearm trial that was designed to detect a relatively robust increase in CD4 + T-cell counts. A larger randomized trial would be needed to demonstrate a smaller effect on CD4 + T-cell increase.
Because we did not have a control group, the changes in immune activation markers may have been due to factors other than maraviroc. Immunophenotyping was performed in real time, and laboratory characteristics or interpretation may have changed over time. The study did not directly evaluate gut-associated lymphoid tissue, which is a major locus of ongoing immune activation. Finally, the prognostic value of the immune activation markers CD38 + and CD38 + /HLA-DR + was established originally in untreated HIV-1 infection [35] . Less is known about the relationship of these markers to long-term outcomes for those with sustained virologic suppression on ART. In summary, the addition of maraviroc was not associated with a clinically significant increase in CD4 + T-cell counts in our trial. Our study does not support the strategy of adding maraviroc to increase CD4+ T-cell counts. We did find a decrease in markers of immune activation and reduced T-cell apoptosis. However, further studies are needed to confirm this Maraviroc was received from baseline to week 24.
Abbreviations: CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein 1; MCP-2, monocyte chemoattractant protein 2; MMP-9, matrix metalloproteinase 9; sCD14, soluble CD14; sICAM-1, soluble intercellular cell adhesion molecule 1; sTNF-RII, soluble tumor necrosis factor receptor type II.
effect. There is growing evidence linking immune activation and end-organ disease. However, much work is needed to define the key components in the cascade of events resulting in immune activation in HIV-1-infected patients. Ultimately, large-scale clinical trials with morbidity and mortality outcomes will be needed before novel therapies targeting immune activation can be recommended for clinical practice.
Notes
